Targeted toxicants to dopaminergic neuronal cell death

Neuronal Cell Death: Methods and Protocols

Volumn , Issue , 2014, Pages 239-252

  Jin, Huajun ^a   Kanthasamy, Arthi ^a   Harischandra, Dilshan S ^a   Anantharam, Vellareddy ^a   Rana, Ajay ^b,c   Kanthasamy, Anumantha ^a  

^a IOWA STATE UNIVERSITY   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Animal model; Dopaminergic neurons; Immunostaining; MPP+; MPTP; Neurodegeneration; Parkinson's disease; Primary mesencephalic cultures; Tyrosine hydroxylase

Indexed keywords

EID: 84922011553     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4939-2152-2_18     Document Type: Chapter

References (42)

1. Jankovic J (1988) Parkinson's disease: recent advances in therapy. South Med J 81: 1021-1027
2. Tanner CM (1992) Epidemiology of Parkinson's disease. Neurol Clin 10: 317-329
3. Przedborski S, Jackson-Lewis V, Djaldetti R et al (2000) The parkinsonian toxin mptp:action and mechanism. Restor Neurol Neurosci 16: 135-142
4. Przedborski S, Dawson TM (2001) The role of nitric oxide in Parkinson's disease. Meth Mol Med 62: 113-136
5. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39: 889-909
6. Abou-Sleiman PM, Muqit MM, Wood NW (2006) Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 7: 207-219
7. Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5: 235-245
8. Magerkurth C, Schnitzer R, Braune S (2005) Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life. Clin Auton Res 15: 76-82
9. Olanow CW (2004) The scientific basis for the current treatment of Parkinson's disease. Annu Rev Met 55: 41-60
10. Obeso JA, Rodriguez-Oroz MC, Goetz CG et al (2010) Missing pieces in the Parkinson's disease puzzle. Nature Med 16: 653-661
11. Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5- hydroxytryptophan as reserpine antagonists. Nature 180: 1200
12. Lewitt PA (2008) Levodopa for the treatment of Parkinson's disease. New Engl J Med 359: 2468-2476
13. Manning-Bog AB, Langston JW (2007) Model fusion, the next phase in developing animal models for Parkinson's disease. Neurotoxicity Res 11: 219-240
14. Jenner P (2008) Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Ann Neurol 64(Suppl 2):S16-S29
15. Langston JW, Ballard P, Tetrud JW et al (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980
16. Hartley A, Stone JM, Heron C et al (1994) Complex i inhibitors induce dose-dependent apoptosis in pc12 cells: relevance to Parkinson's disease. J Neurochem 63: 1987-1990
17. Schapira AH (1993) Mitochondrial complex i deficiency in Parkinson's disease. Adv Neurol 60: 288-291
18. Ramsay RR, Salach JI, Dadgar J et al (1986) Inhibition of mitochondrial nadh dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochem Biophys Res Commun 135: 269-275
19. Schober A (2004) Classic toxin-induced animal models of Parkinson's disease: 6-ohda and mptp. Cell Tiss Res 318: 215-224
20. Przedborski S, Jackson-Lewis V, Naini AB et al (2001) The parkinsonian toxin 1-methyl- 4- phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 76: 1265-1274
21. McGeer PL, McGeer EG (2008) Glial reactions in Parkinson's disease. Mov Disord 23: 474-483
22. Jin H, Kanthasamy A, Ghosh A et al (2011) Alpha-synuclein negatively regulates protein kinase cdelta expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity. J Neurosci 31: 2035-2051
23. Jin H, Kanthasamy A, Anantharam V et al (2011) Transcriptional regulation of proapoptotic protein kinase cdelta: implications for oxidative stress-induced neuronal cell death. J Biol Chem 286: 19840-19859
24. Kanthasamy AG, Anantharam V, Zhang D et al (2006) A novel peptide inhibitor targeted to caspase-3 cleavage site of a proapoptotic kinase protein kinase C delta (PKCdelta) protects against dopaminergic neuronal degeneration in Parkinson's disease models. Free Radic Biol Med 41: 1578-1589
25. Ghosh A, Chandran K, Kalivendi SV et al (2010) Neuroprotection by a mitochondriatargeted drug in a Parkinson's disease model. Free Radical Biol Med 49: 1674-1684
26. Bayer SA, Wills KV, Triarhou LC et al (1995) Time of neuron origin and gradients of neurogenesis in midbrain dopaminergic neurons in the mouse. Exp Brain Res 105: 191-199
27. Ang SL (2006) Transcriptional control of midbrain dopaminergic neuron development. Development 133: 3499-3506
28. Jonsson ME, Ono Y, Bjorklund A et al (2009) Identification of transplantable dopamine neuron precursors at different stages of midbrain neurogenesis. Exp Neurol 219: 341-354
29. Takeshima T, Shimoda K, Johnston JM et al (1996) Standardized methods to bioassay neurotrophic factors for dopaminergic neurons. J Neurosci Meth 67: 27-41
30. Brewer GJ, Torricelli JR, Evege EK et al (1993) Optimized survival of hippocampal neurons in b27-supplemented neurobasal, a new serumfree medium combination. J Neurosci Res 35: 567-576
31. Brewer GJ (1995) Serum-free b27/neurobasal medium supports differentiated growth of neurons from the striatum, substantia nigra, septum, cerebral cortex, cerebellum, and dentate gyrus. J Neurosci Res 42: 674-683
32. Kittappa R, Chang WW, Awatramani RB et al (2007) The foxa2 gene controls the birth and spontaneous degeneration of dopamine neurons in old age. PLoS Biol 5: e325
33. Blakely BD, Bye CR, Fernando CV et al (2011) Wnt5a regulates midbrain dopaminergic axon growth and guidance. PloS One 6: e18373
34. Szabo SE, Monroe SL, Fiorino S et al (2004) Evaluation of an automated instrument for viability and concentration measurements of cryopreserved hematopoietic cells. Lab Hematol 10: 109-111
35. O'Malley EK, Black IB, Dreyfus CF (1991) Local support cells promote survival of substantia nigra dopaminergic neurons in culture. Exp Neurol 112: 40-48
36. Liu B, Linley JE, Du X et al (2010) The acute nociceptive signals induced by bradykinin in rat sensory neurons are mediated by inhibition of m-type K + channels and activation of Ca 2+ - activated Cl - channels. J Clin Invest 120: 1240-1252
37. Seroogy KB, Gall CM (1993) Expression of neurotrophins by midbrain dopaminergic neurons. Exp Neurol 124: 119-128
38. Blesa J, Phani S, Jackson-Lewis V et al (2012) Classic and new animal models of Parkinson's disease. J Biomed Biotechnol 2012: 845618
39. Ghosh A, Saminathan H, Kanthasamy A et al (2013) The peptidyl-prolyl isomerase Pin1 upregulation and proapoptotic function in dopaminergic neurons: relevance to the pathogenesis of Parkinson disease. J Biol Chem 288: 21955-21971
40. Heikkila RE, Hess A, Duvoisin RC (1984) Dopaminergic neurotoxicity of 1-methyl- 4- phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224: 1451-1453
41. Seniuk NA, Tatton WG, Greenwood CE (1990) Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res 527: 7-20
42. Paxinos G, Franklin KBJ (2001) The mouse brain in stereotaxic coordinates, 2nd edn. Academic, San Diego